Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib

BACKGROUND: At present, there is no standard for the posterior treatment of hepatocellular carcinoma (HCC). This study isTo evaluate and compare the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with regorafenib and anti-PD-1 antibody with continued TACE combined wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haochen, Xiao, Weizhong, Han, Yanjing, Cao, Shasha, Zhang, Zhiyuan, Chen, Guang, Hu, Yuefeng, Jin, Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459176/
https://www.ncbi.nlm.nih.gov/pubmed/36092351
http://dx.doi.org/10.21037/jgo-22-626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459176/
https://www.ncbi.nlm.nih.gov/pubmed/36092351
http://dx.doi.org/10.21037/jgo-22-626

Ejemplares similares